The Latest Breaking News from Leukemia

BMO Capital initiated coverage on Beam Therapeutics Inc (NASDAQ:BEAM) with a Market Perform rating and a price target of 41. BMO writes that it appreciates the high potential of Beam's next-generation editing approach, but clinical validation is yet to be established. Preclinical base editing data point to a favorable benefit/risk profile. Also Read: Pfizer, Beam…

LAVA Therapeutics N.V. (NASDAQ:LVTX) hosted a clinical update call focused on initial Phase 1/2a data for LAVA-051 in patients with chronic lymphocytic leukemia (CLL) and multiple myeloma (MM) at the American Society of Clinical Oncology and European Hematology Association meetings. "Although preliminary, these data support our view of LAVA-051 as a promising candidate…

Chardan analyst Matthew Barcus lowered the price target on Vincerx Pharma Inc (NASDAQ:VINC) to $4 from $11 and kept a Buy rating on the shares.  The company announced a strategic update to focus on its Phase Ib development of lead program VIP152 in double-hit diffuse large B-cell lymphoma and chronic lymphocytic leukemia. It also…

The FDA signaled in briefing documents released that it may approve Bluebird bio Inc's (NASDAQ:BLUE) beti-cel gene therapy to treat β-thalassemia for those who require regular blood transfusions. The Prescription Drug User Fee Act (PDUFA) goal dates for beti-cel and eli-cel are August 19 and September 16. Bluebird bio's blood disorder treatment demonstrates "clinically meaningful"…

A metal detectorist couple unearthed five rare 14th-century gold coins from the reign of Edward III in a field that could fetch up to £15,000 – and the find happened while one of them was suffering from leukemia.

Liv Dickson's determination to beat the disease has inspired her dad Allan to taken on a massive charity effort to raise money to help develop new treatments, and he will cycle the 3,500km Tour de France route next month.

Roberta Drury grew up in the Syracuse area and moved to Buffalo a decade ago to help tend to her brother in his fight against leukemia. She was remembered for her love for family and friends.

The FDA has instituted a clinical hold on Foghorn Therapeutics Inc's (NASDAQ:FHTX) Phase 1 dose-escalation study of FHD-286 in relapsed and/or refractory acute myelogenous leukemia (AML) and myelodysplastic syndrome (MDS).  The FDA initiated the partial clinical hold following the report of a recent death that occurred in a subject with potential differentiation syndrome.  Differentiation…

Magenta Therapeutics Inc (NASDAQ:MGTA) shared preliminary data from the Phase 1/2 dose-escalation trial of MGTA-117 in relapsed/refractory acute myeloid leukemia (AML) and myelodysplastic syndrome with excess blasts. The data comes from a Cohort 1, evaluating the lowest dose of MGTA-117 (0.02 mg/kg). Three patients completed the safety evaluation period.  A fourth patient with…

"Its pretty horrific all the time but the hope that this might be her cure is getting us through"

Here's a roundup of top developments in the biotech space over the last 24 hours: